|Bid||0.0000 x 3200|
|Ask||0.0000 x 1000|
|Day's Range||0.7332 - 0.8199|
|52 Week Range||0.5000 - 3.2600|
|Beta (3Y Monthly)||1.43|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.
Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.
After wallowing in penny stock territory until mid-July, the stock has broken the downtrend seen since early March and is experiencing some upward momentum. The company bought the rights to the investigational asset from Questcor Pharma in 2007 by paying $650,000 upfront and an additional $500,000 in May 2014 as a milestone payment. It is being evaluated as a treatment option for relieving symptoms in adult women with acute and recurrent diabetic gastroparesis.
During Evoke Pharma's (EVOK) Q1 conference call, investor focus will be on its progress and issues related to the NDA submission for Gimoti to treat diabetic gastroparesis.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We're definitely into long term investing, but some companies are simply bad investments over any ti...
Dr. Reddy's (RDY) inks agreement to acquire the yet-to-be-marketed portfolio of 42 non-marketed Abbreviated New Drug Applications (ANDAs) in the United States.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 2) Denali Therapeutics Inc (NASDAQ: DNLI ) Dr.Reddy's ...
Biotech stocks came under selling pressure in March, but much of the FDA decisions of the month produced positive results. PDUFA dates are deadlines for the FDA to review new drugs. The FDA is normally ...
Evoke Pharma, Inc.'s (NASDAQ:EVOK): Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development of drugs for the treatment of gastroenterological disorders and diseases. The US$44m market-cap posted Read More...
If you want to know who really controls Evoke Pharma Inc (NASDAQ:EVOK), then you’ll have to look at the makeup of its share registry. Large companies usually have institutions as Read More...